This content is from: Premium Have Tesla Shorts Come Back? Not Yet The big short is still in the red for the year — but the stock is still falling. By Michelle Celarier March 09, 2020
This content is from: Corner Office Short Sellers Hurt by Gilead’s Kite Acquisition Kite Pharma has likely been a target for bearish bets because the cancer-fighting technology it uses — CART — is new to the market, says Wedbush biotechnology analyst David Nierengarten. By Alicia McElhaney August 28, 2017
This content is from: Portfolio Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. By Vitaliy Katsenelson February 23, 2016
This content is from: Premium Druckenmiller’s Family Office Unloads Two Major Stocks The legendary macro trader established more new positions than it liquidated during the second quarter. By Stephen Taub August 28, 2018
This content is from: Premium The Hottest Sector Has Attracted the Most Short Interest Longs and shorts are having a tug-o-war over red-hot biotechnology stocks. By Stephen Taub September 11, 2017
This content is from: Portfolio ‘The Managers of These Companies Are Corporate Sociopaths’ Gabriel Grego loves to fight. But in the age of Covid-19, newly declared short-selling bans threaten his most essential weapon. By Richard Teitelbaum April 07, 2020
Sponsored Material Winners and Losers in ESG Strategies A renowned quant shop rolls out an absolute return innovation that isn’t just long-only. Sponsored by CFM June 30, 2020
